Prelude Therapeutics (PRLD) 주식 개요
임상 단계의 정밀 종양학 회사인 프렐류드 테라퓨틱스는 소외된 환자들을 위한 새로운 정밀 암 치료제를 발견하고 개발하는 데 주력하고 있습니다. 자세히 보기
PRLD Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Prelude Therapeutics Incorporated 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$4.91 |
| 52주 최고가 | US$5.69 |
| 52주 최저가 | US$0.75 |
| 베타 | 0.95 |
| 1개월 변동 | 28.87% |
| 3개월 변동 | 11.59% |
| 1년 변동 | 508.65% |
| 3년 변동 | 7.44% |
| 5년 변동 | -82.29% |
| IPO 이후 변동 | -81.26% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 26
PRLD: Metastatic Breast Cancer Program Will Drive Upside From Early-Stage Platform
The analyst price target for Prelude Therapeutics has been revised higher from $5 to $10, as analysts point to the company's differentiated approach in metastatic breast cancer and the large addressable market opportunity cited in recent research coverage. Analyst Commentary Recent research on Prelude Therapeutics highlights growing interest in the company’s approach to metastatic breast cancer and the potential market it is targeting.분석 기사 • May 16
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...Recent updates
내러티브 업데이트 • Jun 26
PRLD: Metastatic Breast Cancer Program Will Drive Upside From Early-Stage Platform
The analyst price target for Prelude Therapeutics has been revised higher from $5 to $10, as analysts point to the company's differentiated approach in metastatic breast cancer and the large addressable market opportunity cited in recent research coverage. Analyst Commentary Recent research on Prelude Therapeutics highlights growing interest in the company’s approach to metastatic breast cancer and the potential market it is targeting.분석 기사 • May 16
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...
새로운 내러티브 • Mar 06
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?분석 기사 • Dec 03
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk
Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) shares have retraced a considerable 66% in the last month, reversing...Seeking Alpha • Nov 03
Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges
Summary Prelude Therapeutics continues to explore the SMARCA2 anticancer approach, with no major hiccups disclosed to date. A strategic shift from their main pipeline contender raises concerns about data not yet disclosed, however. PRLD's funding situation is also in doubt, as they will find themselves needing to raise cash in the coming months. An upcoming ASH presentation could also shed some light on the next steps for two preclinical projects in myeloproliferative neoplasms. Read the full article on Seeking Alpha분석 기사 • Jun 16
Prelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Mar 17
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Feb 03
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Summary Prelude Therapeutics once produced positive clinical data from a now abandoned program. The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early preclinical data and look scientifically interesting. However, they are too early to merit an investment right now, although they bear watching. Read the full article on Seeking Alpha분석 기사 • Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Oct 18
Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Prelude Therapeutics (NASDAQ:PRLD), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent. A protein degrader targeted at SMARCA2 (BRM) mutations in cancer tissue, PRT3789, has demonstrated antitumor activity in preclinical models at well-tolerated doses, the company said. “Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic,” Dr. Peggy Scherle, Chief Scientific Officer of Prelude (PRLD), noted. The Phase 1 trial for PRT3789 is designed to enroll patients with advanced solid tumors harboring SMARCA4. The dosing is expected to start in Q1 2023. PRLD awaits multiple catalysts in its clinical programs this year.Seeking Alpha • Sep 09
Prelude downgraded at Morgan Stanley ahead of key update
Prelude Therapeutics (NASDAQ:PRLD) inched lower on Friday after Morgan Stanley downgraded the cancer-focused biotech to Equal Weight from Overweight as the company plans to disclose key steps forward for its PRMT5 program, including the solid tumor candidate PRT811 in H2 2022. The analysts see upside potential as PRLD remains on track to report early findings from its MCL1 inhibitor program and CDK9 inhibitor program during the second half of 2022. However, they see better opportunities elsewhere in the coverage noting uncertainty over the path forward for PRT811. Morgan Stanley lowers the probability of success for PRT811 in GBM, solid tumors, and myeloid malignancies to 20% from 25%, in line with the range it usually uses for Phase 1 assets, and trims the price target for PRLD to $11 from $19. Early this year, PRLD decided to drop the development of the PRT543 candidate in its PRMT5 program and focus its efforts on PRT811.분석 기사 • Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...주주 수익률
| PRLD | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -0.4% | 4.1% | 1.6% |
| 1Y | 508.7% | 41.1% | 18.6% |
수익률 대 산업: PRLD은 지난 1년 동안 41.1%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: PRLD은 지난 1년 동안 18.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| PRLD volatility | |
|---|---|
| PRLD Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: PRLD의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: PRLD의 주간 변동성은 지난 1년간 28%에서 17%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2016 | 79 | Kris Vaddi | preludetx.com |
임상 단계의 정밀 종양학 회사인 프렐류드 테라퓨틱스는 소외된 환자들을 위한 새로운 정밀 암 치료제의 발견과 개발에 주력하고 있습니다. 골수 증식성 종양, 골수섬유증(MF), 적혈구증가증, 필수 혈소판 감소증(ET) 치료를 위한 드라이버 변이 제품인 JAK2V617F, 진행성 유방암 및 기타 고형 종양 치료를 위한 KAT6A, MF와 ET 치료를 위한 변이 칼레티쿨린 분해 항체 접합체를 개발 중입니다. 이 회사는 새로운 분해효소 항체 접합체를 발견, 개발 및 상용화하기 위해 AbCellera Biologics와 협력하고 있습니다.
Prelude Therapeutics Incorporated 기초 지표 요약
| PRLD 기초 통계 | |
|---|---|
| 시가총액 | US$486.96m |
| 순이익 (TTM) | -US$77.80m |
| 매출 (TTM) | US$16.72m |
29.1x
주가매출비율(P/S)-6.3x
주가수익비율(P/E)PRLD는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| PRLD 손익계산서 (TTM) | |
|---|---|
| 매출 | US$16.72m |
| 매출원가 | US$0 |
| 총이익 | US$16.72m |
| 기타 비용 | US$94.52m |
| 순이익 | -US$77.80m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.78 |
| 총이익률 | 100.00% |
| 순이익률 | -465.30% |
| 부채/자본 비율 | 0% |
PRLD의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/06 08:26 |
| 종가 | 2026/07/02 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Prelude Therapeutics Incorporated는 6명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |